Cipla Q1 FY26 Results: Mumbai-based drugmaker beats street estimates with Rs 12,98 crore profit; edge stable

Cipla Q1 FY26 results: Mumbai-based pharmaceutical company Cipla reported on Friday that consolidated net profit rose 10.2% year-on-year in the quarter ended June 30, beating analyst expectations. Cipla shares were issued immediately after the earnings announcement as the result was announced in market time, with a 3.0% stability being completed on BSE at a price of Rs 1,531. On NSE, the stock rose 3.2% to sell for Rs 1,535.

Cipla Q1 Revenue | What are the first- and bottom-line fares for pharmaceutical companies and estimates?

Cipla’s revenue in the June quarter was Rs 6,957 crore, up 3.9 per cent from the same period last year, according to regulatory documents. In terms of analyst estimates, the top line also largely matches the mark.

Cipla is expected to have a net profit of Rs 1,174 crore and revenue for the quarter was Rs 6,970 crore, according to Zee Business Research.

“I’m happy to share that we will continue to make a lot of progress in a concentrated market,” said Cipla, MD and global CEO.

Cipla Q1 | Operational Performance

The document noted that the company’s operating profit grew to Rs 17.777 crore from Rs 1,716 crore a year ago.

As in the same period last year, its profit margin remained unchanged at 25.6%. Margin is a key measure of a company’s profitability.

The drug manufacturer’s other revenue jumped 62 per cent to Rs 25.9 crore.

Results and expectations

The results are better than most analysts expected.

According to Zee Business Research, the drugmaker’s financial results are estimated to be 23.99%. ​

The company’s North American revenue fell 7% to Rs 193.3 crore, much better than the 10% drop expected by analysts.

Cipla Share with Nifty 50

At current levels, Cipla shares have seen a year drop of about 2.9% (YTD), which is consistent with Nifty Pharma’s 3.7% drop, but underperformed, with Nifty50 up 4.6%.